Lawsuits Mount Over GLP-1 Drugs and Potential Vision Loss

Wirth is one of many patients now seeking legal recourse, alleging that GLP-1 receptor agonists—a class of drugs including Ozempic, Mounjaro, and Zepbound—are linked to non-arteritic anterior ischemic optic neuropathy (NAION). This condition disrupts blood flow to the optic nerve, often resulting in sudden, irreversible vision loss. While manufacturers maintain that their warning labels are sufficient, plaintiffs argue they were never properly informed of the risks.

Jason S. Goldstein, a senior litigation counsel at Parker Waichman LLP, represents Wirth and serves as a lead liaison in the consolidated federal litigation, MDL No. 3163, currently pending before Judge Karen S. Marston in Pennsylvania. According to Goldstein, the goal is to secure accountability for patients who suffered life-altering injuries without warning. As the scientific and regulatory scrutiny of these medications intensifies, the court must now determine the extent of the manufacturers' liability regarding these optic nerve injuries.